--- title: "BioLineRX (BLRX) news: offering" url: "https://aibio.space/companies/biolinerx/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BLRX offering news: BioLineRx raises $3.75M at $2.78 per ADS with 1.5x warrant coverage. BioLineRX Ltd. (TASE: BLRX), Israel." --- BLRX BioLineRX Ltd. TASE · Israel # BioLineRX (BLRX) news BLRX offering news Financings · 2026-08-28 ## [BioLineRx raises $3.75M at $2.78 per ADS with 1.5x warrant coverage](https://aibio.space/news/biolinerx-raises-3-75m-2-78-ads-1-5x-warrant-coverage/) BioLineRx sold 1,348,921 ADSs at $2.78 each and issued warrants on 2,023,382 more ADSs. It also amended older warrants on 277,273 ADSs and cut its at-the-market facility to zero. ## Latest BioLineRX news We have not published a story on BioLineRX yet. When there is news, it will appear here. ## BioLineRX at a glance - **Ticker**: BLRX - **Listing**: TASE - **Country**: Israel - **Cash, Dec 31, 2025**: $3.2 million ### Related companies - [Nasus Pharma](https://aibio.space/companies/nasus-pharma/) AMEX: NSRX - [MediWound](https://aibio.space/companies/mediwound/) NASDAQ: MDWD - [PRF Technologies](https://aibio.space/companies/prf-technologies/) NASDAQ: PRFX - [Rekah Pharmaceutical Industry](https://aibio.space/companies/rekah-pharmaceutical-industry/) TASE: REKA - [Purple Biotech](https://aibio.space/companies/purple-biotech/) TASE: PPBT - [PolyPid](https://aibio.space/companies/polypid/) NASDAQ: PYPD - [Entera Bio](https://aibio.space/companies/entera-bio/) NASDAQ: ENTX - [Eocene](https://aibio.space/companies/eocene/) NASDAQ: EOCN ### Also on TASE - [Matricelf](https://aibio.space/companies/matricelf/) MTLF - [Purple Biotech](https://aibio.space/companies/purple-biotech/) PPBT - [Teva Pharmaceutical Industries](https://aibio.space/companies/teva-pharmaceutical-industries/) TEVA - [Rafa Laboratories](https://aibio.space/companies/rafa-laboratories/) RAFA - [Psyrex CNS Bio-Tech](https://aibio.space/companies/psyrex-cns-bio-tech/) PSRX - [EPITOMEE MEDICAL LTD](https://aibio.space/companies/epitomee-medical/) EPIT ## BioLineRX annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$1.2 million](https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/) | [$28.9 million](https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/) | | Research and development | [$8.1 million](https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/) | [$9.1 million](https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/) | | Net income (loss) | [-$2.0 million](https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/) | [-$9.2 million](https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/) | | Cash from operations | [-$8.1 million](https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/) | [-$43.9 million](https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/) | | Cash and equivalents | [$3.2 million](https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/) | [$10.4 million](https://www.sec.gov/Archives/edgar/data/1498403/000117891326001581/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $3.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about BioLineRX Has BioLineRX raised money recently? Our latest story on this, dated Aug 28, 2026: "BioLineRx raises $3.75M at $2.78 per ADS with 1.5x warrant coverage". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/biolinerx-raises-3-75m-2-78-ads-1-5x-warrant-coverage/). What is the ticker symbol of BioLineRX? BioLineRX Ltd. trades under the ticker BLRX on TASE. Where is BioLineRX listed? BioLineRX Ltd. is listed on TASE. Our directory also records these other listings: NASDAQ:BLRX. What is the SEC CIK of BioLineRX? The SEC Central Index Key (CIK) for BioLineRX Ltd. is 1498403. Its filings are on SEC EDGAR. How many shares does BioLineRX have outstanding? 2,610,814,390 shares as of 2026-03-08, per the cover page of its 20-F filed 2026-03-23. Which country or territory is BioLineRX listed under? Our directory records BioLineRX Ltd. under Israel. What does BioLineRX do? Our directory classifies BioLineRX Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of BioLineRX? The ISIN recorded for BioLineRX Ltd. is IL0011015182. Does aibio.space cover BioLineRX? aibio.space lists BioLineRX Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is BioLineRX incorporated? SEC records list its state or country of incorporation as L3. What was BioLineRX's revenue last year? $1.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is BioLineRX profitable? BioLineRX Ltd. reported a net loss of $2.0 million for the fiscal year ended Dec 31, 2025, and used $8.1 million of cash in operations, per its annual report to the SEC. How much does BioLineRX spend on research and development? $8.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does BioLineRX have? $3.2 million in cash at Dec 31, 2025, per its 20-F. What is the latest BioLineRX (BLRX) stock news? Our latest story on BioLineRX, dated Aug 28, 2026: "BioLineRx raises $3.75M at $2.78 per ADS with 1.5x warrant coverage". BioLineRx sold 1,348,921 ADSs at $2.78 each and issued warrants on 2,023,382 more ADSs. It also amended older warrants on 277,273 ADSs and cut its at-the-market facility to zero. [Source](https://aibio.space/news/biolinerx-raises-3-75m-2-78-ads-1-5x-warrant-coverage/). ## Investor discussion: BioLineRX Members talk about BioLineRX (BLRX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at BioLineRX, newest first. Each line links the filing it comes from. 1. 2026-08-28 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1498403/000117891326004292/zk2636027.htm) 2. 2025-03-31 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1498403/000117891325001123/zk2532907.htm) 3. 2024-11-21 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1498403/000117891324003790/zk2432371.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open TASE:BLRX on TradingView](https://www.tradingview.com/symbols/TASE-BLRX/). ## SEC filings and registration - **SEC name**: BioLineRx Ltd. - **CIK**: 1498403 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: BLRX (Nasdaq) - **State or country of incorporation**: L3 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer - **Business address**: 2 HAMAAYAN STREET, MODI-IN, ISRAEL - **Phone**: 972-8-642-9100 - **Shares outstanding**: 2,610,814,390 as of 2026-03-08 (20-F filed 2026-03-23) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1498403/000117891326004591/zk2636152.htm) filed 2026-09-24 - [6-K](https://www.sec.gov/Archives/edgar/data/1498403/000117891326004479/zk2636104.htm) filed 2026-09-10 - [424B5](https://www.sec.gov/Archives/edgar/data/1498403/000117891326004339/zk2636034.htm) filed 2026-08-31 - [6-K](https://www.sec.gov/Archives/edgar/data/1498403/000117891326004334/zk2636031.htm) filed 2026-08-31 - [6-K](https://www.sec.gov/Archives/edgar/data/1498403/000117891326004331/zk2635990.htm) filed 2026-08-31 - [6-K](https://www.sec.gov/Archives/edgar/data/1498403/000117891326004292/zk2636027.htm) filed 2026-08-28 - [6-K](https://www.sec.gov/Archives/edgar/data/1498403/000117891326004184/zk2635976.htm) filed 2026-08-18 - [6-K](https://www.sec.gov/Archives/edgar/data/1498403/000117891326003438/zk2635661.htm) filed 2026-07-08 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001498403), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details BioLineRX Ltd. is a public biotech or pharmaceutical company listed on TASE under the ticker BLRX, recorded under Israel. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: BioLineRX Ltd. - **Ticker**: BLRX - **Listing**: TASE - **Country or territory**: Israel - **Business scope**: Pharmaceuticals: Major - **ISIN**: IL0011015182 - **Other listed symbols**: NASDAQ:BLRX - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/TASE-BLRX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/biolinerx/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BioLineRX (BLRX) news: offering", 2026-10-31, https://aibio.space/companies/biolinerx/